Recombinant Human Granulocyte/Macrophage Colonystimulating Factor(rhGM-CSF)

Generic Name
Recombinant Human Granulocyte/Macrophage Colonystimulating Factor(rhGM-CSF)
Brand Names
-
Drug Type
-
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
-
Indication

用于:1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染;

2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥;

3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员;

4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少;

5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。

Associated Conditions
-
Associated Therapies
-

Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma

Phase 2
Completed
Conditions
First Posted Date
2008-02-15
Last Posted Date
2012-05-03
Lead Sponsor
Mt. Sinai Medical Center, Miami
Target Recruit Count
36
Registration Number
NCT00616564
Locations
🇺🇸

Jose Lutzky, MD, Miami Beach, Florida, United States

🇺🇸

David Lawson, MD, Atlanta, Georgia, United States

Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma

First Posted Date
2007-08-08
Last Posted Date
2013-03-01
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
9
Registration Number
NCT00512889
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients

First Posted Date
2007-07-11
Last Posted Date
2013-08-02
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
84
Registration Number
NCT00499343
Locations
🇺🇸

U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2007-05-22
Last Posted Date
2017-11-29
Lead Sponsor
Stanford University
Target Recruit Count
10
Registration Number
NCT00477087
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma

First Posted Date
2007-04-04
Last Posted Date
2018-01-18
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
3
Registration Number
NCT00455897
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer

First Posted Date
2007-03-21
Last Posted Date
2016-03-17
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
9
Registration Number
NCT00450008
Locations
🇺🇸

The Methodist Hospital Research Institute, Houston, Texas, United States

Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-03-16
Last Posted Date
2016-03-17
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
27
Registration Number
NCT00448409
Locations
🇺🇸

The Methodist Hospital Research Institute, Houston, Texas, United States

Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer

First Posted Date
2007-03-14
Last Posted Date
2016-03-17
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
31
Registration Number
NCT00447473
Locations
🇺🇸

Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States

Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia

First Posted Date
2007-03-12
Last Posted Date
2015-08-25
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT00446173
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath